A 28-year-old male laborer from Jharkhand presents with a 7-day history of fever, severe headache, confusion, and two episodes of generalized tonic-clonic seizures. On examination, he is febrile (40.2°C), with altered mental status (Glasgow Coma Scale 12/15), neck stiffness, and hepatosplenomegaly. Fundoscopy reveals retinal hemorrhages and cotton-wool spots. Thick blood smear shows parasitemia of 8% with banana-shaped gametocytes. Serum glucose is 32 mg/dL, lactate 6.2 mmol/L, and hemoglobin 7.8 g/dL. What is the most appropriate immediate management?

Explanation

## Severe Malaria Management: Artesunate is First-Line ### Clinical Diagnosis: Severe Plasmodium falciparum Malaria with Cerebral Involvement **Key Point:** This patient has **cerebral malaria** (altered consciousness + parasitemia + exclusion of other causes) with severe complications: hypoglycemia, lactic acidosis, severe anemia, and high parasitemia (8%). This is a medical emergency requiring **intravenous artesunate**. ### Why Artesunate is Superior **High-Yield:** The WHO and Indian guidelines (2019) recommend **intravenous artesunate as first-line** for severe malaria, including cerebral malaria, because: 1. **Faster parasite clearance** — reduces parasitemia by ~50% every 48 hours vs. 72 hours with quinine 2. **Superior mortality reduction** — 35% relative risk reduction compared to quinine in severe malaria 3. **Better CNS penetration** — achieves higher CSF concentrations 4. **Fewer adverse effects** — no hypoglycemia risk (unlike quinine), no arrhythmias 5. **Rapid onset** — therapeutic levels within 30 minutes of IV administration ### Artesunate Dosing Regimen | Phase | Dose | Frequency | Duration | | --- | --- | --- | --- | | **Acute** | 2.4 mg/kg IV | 0, 12, 24 hours | First 3 doses | | **Maintenance** | 2.4 mg/kg IV | Once daily | Until oral therapy tolerated (minimum 3 days) | | **Switch to oral** | ACT (e.g., artemether-lumefantrine) | As per regimen | Complete 3-day course | **Clinical Pearl:** Artesunate must be reconstituted with 5.3 mL of 5% sodium bicarbonate (provided in vial), NOT saline, to ensure dissolution and bioavailability. ### Management of Complications in This Patient ```mermaid flowchart TD A[Severe P. falciparum malaria]:::outcome --> B{Complications?}:::decision B -->|Cerebral malaria| C[Airway protection, ICU monitoring]:::action B -->|Hypoglycemia| D[IV dextrose 50% bolus, then infusion]:::action B -->|Lactic acidosis| E[Fluid resuscitation, supportive care]:::action B -->|Severe anemia| F[Transfuse if Hb < 7 or symptomatic]:::action B -->|Seizures| G[Benzodiazepines, prophylactic phenytoin]:::action C --> H[IV Artesunate 2.4 mg/kg]:::action D --> H E --> H F --> H G --> H H --> I[Monitor parasitemia, glucose, lactate q12h]:::action I --> J[Switch to oral ACT when conscious]:::action ``` **Mnemonic: SEVERE MALARIA FEATURES** — **S**eizures, **E**ncephalopathy, **V**ery high parasitemia (>5%), **E**dema (pulmonary/cerebral), **R**enal failure, **E**ver-high fever ### Why Other Options Are Suboptimal | Drug | Why Not First-Line | | --- | --- | | **Quinine** | Slower parasite clearance, hypoglycemia risk (stimulates pancreatic insulin), arrhythmias, lower mortality benefit | | **Oral artemether-lumefantrine** | Contraindicated in altered consciousness (aspiration risk), slow absorption, inadequate for cerebral malaria | | **IM artemether** | Slower onset than IV, less predictable absorption, not preferred for severe disease | **Warning:** Do NOT delay artesunate while awaiting confirmatory tests. Presumptive treatment is justified given high parasitemia + clinical features of cerebral malaria. ### Supportive Measures (Concurrent with Artesunate) 1. **Hypoglycemia** — IV dextrose 50% 50 mL bolus, then 5–10% dextrose infusion 2. **Seizures** — Benzodiazepines (lorazepam 4 mg IV), consider prophylactic phenytoin 3. **Anemia** — Transfuse PRBCs if Hb <7 g/dL or symptomatic 4. **Lactic acidosis** — Fluid resuscitation (cautious, avoid overload), treat underlying cause 5. **Monitoring** — ICU-level care with hourly glucose, 12-hourly parasitemia, daily renal function [cite:Harrison 21e Ch 218; WHO Guidelines on Malaria 2021]